Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/185934
Title: | SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
Author: | Piñana, José Luis López Corral, Lucia Martino, Rodrigo Vazquez, Lourdes Pérez, Ariadna Martin Martin, Gabriel Gago, Beatriz Sanz Linares, Gabriela Sánchez Salinas, Andrés Villalón, Lucia Conesa García, Venancio Olave, María T. Corona, Magdalena Marcos Corrales, Sara Tormo, Mar Hernández Rivas, José Ángel Montoro, Juan Rodriguez Fernandez, Alicia Risco Gálvez, Irene Rodríguez Belenguer, Pablo Hernandez Boluda, Juan Carlos García Cadenas, Irene Ruíz García, Montserrat Muñoz Bellido, Juan Luis Solano, Carlos Cedillo, Ángel Sureda, Anna Navarro, David Infectious Complications Subcommittee Of The Spanish Hematopoietic Stem Cell Transplantation And Cell Therapy Group (GETH-TC) |
Keywords: | SARS-CoV-2 Vacunació Malalties hematològiques SARS-CoV-2 Vaccination Hematologic diseases |
Issue Date: | 7-May-2022 |
Publisher: | Springer Science and Business Media |
Abstract: | Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3-6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 days (range 7-195) after full vaccination. The incidence rate was 6.39 per 100 persons-year. Most patients were asymptomatic (19/37, 51.4%), whereas only 19% developed pneumonia. The mortality rate was 8%. Lack of detectable antibodies at 3-6 weeks after full vaccination was the only variable associated with breakthrough infection in multivariate logistic regression analysis (Odds Ratio 2.35, 95% confidence interval 1.2-4.6, p = 0.012). Median antibody titers were lower in cases than in non-cases [1.83 binding antibody units (BAU)/mL (range 0-4854.93) vs 730.81 BAU/mL (range 0-56,800), respectively (p = 0.007)]. We identified 250 BAU/mL as a cutoff above which incidence and severity of the infection were significantly lower. Conclusions Our study highlights the benefit of developing an antibody response in these highly immunosuppressed patients. Level of antibody titers at 3 to 6 weeks after 2-dose vaccination links with protection against both breakthrough infection and severe disease for non-Omicron SARS-CoV-2 variants. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s13045-022-01275-7 |
It is part of: | Journal of Hematology & Oncology, 2022, vol. 15, num. 1 |
URI: | http://hdl.handle.net/2445/185934 |
Related resource: | https://doi.org/10.1186/s13045-022-01275-7 |
ISSN: | 1756-8722 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s13045-022-01275-7.pdf | 893.94 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License